More on ACHFF
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $0.64 |
|
|||
| Open | $0.63 | ||||
| 52 Wk High | $ | ||||
| 52 Wk Low | $ | ||||
| Day High | $0.67 | ||||
| Day Low | $0.63 | ||||
| P/E | N/A | ||||
| EPS | $ | ||||
| Volume | 13,575 | ||||
- Arch Biopartners Engages Private Laboratory to Accelerate IL-32 Chronic Kidney Disease Program
- Arch Biopartners Featured in American Diabetes Association Thought Leadership Series at the 2026 Scientific Sessions in New Orleans
- Arch Biopartners announces Royal Columbian Hospital has dosed its first patient in its Phase II cardiac surgery-associated AKI trial
- Royal Columbian Hospital begins patient recruitment in Arch Biopartners’ Phase II trial of LSALT peptide targeting CS-AKI
- Arch Biopartners raises $600,000 in private placement offering
- Arch Biopartners Closes Non-Brokered Private Placement
- Arch Biopartners arranges $600,000 private placement at $0.60 per share
- Arch Biopartners Arranges Non-Brokered Private Placement
- Arch Biopartners and the Fraser Health Authority enter into a Clinical Trial Agreement for the Phase II Cardiac Surgery-Associated AKI Trial
- Arch Biopartners Scientists Publish New Data Linking the Cytokine IL-32 to Inflammation and Diabetic Kidney Disease
Entities mentioned with ACHFF
- FDA | View Related Stories »
- Twitter | View Related Stories »
- Definitive Agreement | View Related Stories »
- Show More...
